HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker
Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine), Luigi Terracciano(Humanitas University), P Rossi(University of Rome Tor Vergata), Giandomenica Iezzi(Ente Ospedaliero Cantonale), Roberto Arriga(University of Rome Tor Vergata), Soldano Ferrone(Massachusetts General Hospital), Serenella Eppenberger‐Castori(Unknown), Sara Caratelli(National Academies of Sciences, Engineering, and Medicine), Luigi Tornillo(University of Basel), Giulio C. Spagnoli(National Academies of Sciences, Engineering, and Medicine), Raoul A. Droeser(University of Basel), Davide Lauro(University of Rome Tor Vergata), Eva Karamitopoulou(Programs for Assessment of Technology in Health Research Institute), Alessandro Lugli(University of Bern), Cristina R. Ferrone(Cedars-Sinai Medical Center), Inti Zlobec(University of Bern), Junyi Han(National Cancer Center), Andrea Coppola(University of Rome Tor Vergata), Antonio Attanasio(University of Rome Tor Vergata), Amedeo Ferlosio(University of Rome Tor Vergata)
Cited by 141
Related Papers
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
|Annals of Surgery|2014|841
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
|JAMA Oncology|2018|549